Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Ventana Signs Companion Diagnostic Agreement for Genmab Antibody-Drug Conjugate

By BiotechDaily International staff writers
Posted on 14 Apr 2014
Ventana Medical Systems, Inc. (Ventana; Tucson, AZ, USA), a member of the Roche Group (Basel, Switzerland), has entered into an agreement with Genmab A/S (Copenhagen, Denmark) for the development of companion diagnostic (CDx) tools for Genmab's "HuMax-TF-ADC" antibody-drug conjugate (ADC) program. As part of the agreement, Ventana will provide its expertise and services towards the development of an immunohistochemistry (IHC) companion diagnostic test for the detection of tissue factor (TF) in patient tumor samples. The TF assay will be developed for possible designation as the screening test in clinical trials involving HuMax-TF-ADC.

CDx tests, designed to detect the presence of specific biomarkers, assist clinicians in selecting effective therapies and in identifying the patients most likely to respond favorably to specific therapies. Incorporating a companion diagnostic strategy into a drug development program may help generate more effective drugs with improved safety profiles for patients. Ventana has worked with more than 45 biopharmaceutical partners and is currently engaged in more than 180 collaborative projects to develop and commercialize companion diagnostics globally. The company has a global install base of over 10,000 automated platforms that run advanced cancer diagnostic tests.

Via antibody conjugation to potent cytotoxic drugs, ADCs for cancer therapy can increase efficacy and reduce systemic toxicity of drugs by targeting them selectively to tumor cells The targeted nature of ADCs make them good candidates for codevelopment with the Ventana IHC-based companion diagnostic assays that measure tumor-specific antigens.

"We are pleased to work with Genmab to develop a companion diagnostic for HuMax-TF-ADC," said Ventana President Mara G. Aspinall. "This agreement is in 100% alignment with our CDx strategy and our ever-growing lineup of global pharma partnerships designed to bring promising therapies to market faster to improve the lives of cancer patients."

Related Links:

Ventana Medical Systems
Genmab 
Roche



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Difference in DP103 (red) levels in a healthy person (left image) and a breast cancer patient (right image) (Photo courtesy of the National University of Singapore).

BP103 Cited as Breast Cancer Biomarker and Potential Treatment Target

Cancer researchers in Singapore have identified the DP103 oncogene in human breast cancers as a biomarker for the molecular processes that drive reappearance and metastasis of tumors following chemotherapy.... Read more

Drug Discovery

view channel
Image: (Left) Neurons in brains from people with autism do not undergo normal pruning during childhood and adolescence. The images show representative neurons from unaffected brains (left) and brains from autistic patients (right); the spines on the neurons indicate the location of synapses (Photo courtesy of Guomei Tang, PhD and Mark S. Sonders, PhD, Columbia University Medical Center).

Autistic Youngsters Found to Have Too Many Brain Synapses

Autistic children and adolescents have been shown to have an excess of brain synapses, and this is due to a slowdown in the normal brain “trimming” process during development, according to new findings.... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Assessing Myeloma Progression Using Calcium Isotope Analysis

Scientists are revealing how an Earth science research principle can be used in biomedical situations to predict the development of disease. The researchers evaluated a new approach to detecting bone loss in cancer patients by using calcium isotope analysis to predict whether myeloma patients are at risk for developing... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.